The PCM program has been built up in three phases: during 2014-2017 we focused on building the back office and mapping the challenges (through eight investigations and supporting four pilot projects), 2017-2019 the focus was on implementation through linking up with CCE, launching the first PCM trial with CCE, BoB and building the molecular tumor board, primarily for that trial. 2020-22 will focus on expanding into several clinical trials and catalyzing the creation of a molecular diagnostics center.